The FDA's guidance on the Phase 2 study design is a critical regulatory step for Processa Pharmaceuticals, indicating that the company is on the right track with its development plans. This news is likely to be viewed positively by investors, as it suggests progress in the company's pipeline and potential future revenue from the cancer treatment if it is successful. The direct involvement of the FDA and the focus on advancing to the next phase of clinical trials could lead to increased investor confidence and a potential short-term uptick in the stock price.